Tissue plasminogen activator: peptide analyses confirm an indirectly derived amino acid sequence, identify the active site serine residue, establish glycosylation sites, and localize variant differences
about
The relationship of N-linked glycosylation and heavy chain-binding protein association with the secretion of glycoproteinsLocalization of the binding site of tissue-type plasminogen activator to fibrinImpacts of tissue-type plasminogen activator (tPA) on neuronal survivalThe axonally secreted serine proteinase inhibitor, neuroserpin, inhibits plasminogen activators and plasmin but not thrombin.Involvement of finger domain and kringle 2 domain of tissue-type plasminogen activator in fibrin binding and stimulation of activity by fibrinThe hydroxy amino acid in an Asn-X-Ser/Thr sequon can influence N-linked core glycosylation efficiency and the level of expression of a cell surface glycoprotein.The amino acid at the X position of an Asn-X-Ser sequon is an important determinant of N-linked core-glycosylation efficiency.Carbohydrate analysis throughout the development of a protein therapeutic.Regulation of N-linked core glycosylation: use of a site-directed mutagenesis approach to identify Asn-Xaa-Ser/Thr sequons that are poor oligosaccharide acceptors.N-glycoprotein macroheterogeneity: biological implications and proteomic characterization.Translational initiatives in thrombolytic therapy.Plasminogen activation: biochemistry, physiology, and therapeutics.Plasminogen activators and their potential in therapy.Glycosylation and secretion of human tissue plasminogen activator in recombinant baculovirus-infected insect cells.Conservation of the kinaselike regulatory domain is essential for activation of the natriuretic peptide receptor guanylyl cyclases.Reduction of endogenous GRP78 levels improves secretion of a heterologous protein in CHO cells.A family of novel, acidic N-glycans in Bowes melanoma tissue plasminogen activator have L2/HNK-1-bearing antennae, many with sulfation of the fucosylated chitobiose core.Variants of human tissue-type plasminogen activator that lack specific structural domains of the heavy chain.The glycosylation of Bowes melanoma tissue plasminogen activator: lectin mapping, reaction with anti-L2/HNK-1 antibodies and the presence of sulphated/glucuronic acid containing glycansBinding of tissue plasminogen activator to human aortic endothelial cells.Comparison of clot lysis activity and biochemical properties of originator tenecteplase (Metalyse(®)) with those of an alleged biosimilarThe mechanism of the reaction between human plasminogen-activator inhibitor 1 and tissue plasminogen activator.Cell-free synthesis of enzymically active tissue-type plasminogen activator. Protein folding determines the extent of N-linked glycosylation.crosslinked fibrin multimer + tissue plasminogen activator (one-chain) -> crosslinked fibrin multimer:tissue plasminogen activator (one-chain)Tissue-type plasminogen activator as a therapeutic target in strokeHeterogeneity of human tissue-type plasminogen activatorIn silico and in vivo analyses of the mutated human tissue plasminogen activator (mtPA) and the antithetical effects of P19 silencing suppressor on its expression in two Nicotiana species
P2860
Q24296449-42C01846-4B33-440D-84E7-9DD16B9E2E0CQ24622922-B703814E-7030-4FB7-BF88-921AB7C428F6Q26777261-BBA7BE66-0053-4F86-A2CE-B6049AA8FEA1Q29465797-28944E4C-A701-454E-8886-E7AC3F57ADF3Q33881226-5AAE09A8-4A36-4A3C-A296-AAAC6FF7A0DDQ34059024-C91BF46D-4FA2-474A-8830-34D7D1E55A80Q34062516-ABB228BE-C306-49E7-8325-F359471C3173Q37627225-EA3CF043-843B-48DE-8DFE-9BC2DFB92A2AQ38346775-0D325474-1269-47E2-BD55-89093ED6E1A6Q38659790-6A182EDF-2F93-4474-BF51-03BC58B72872Q39100187-AD653CC3-3FEB-4D62-A204-CAA566377412Q39489577-AB70AEEF-17D3-46A6-B518-36C78E598349Q39608571-9ED77588-1832-44A7-B868-FB2A21AD3711Q40644152-B6E65EB4-84C7-4843-AEA0-4E2BA43E9C56Q40655018-7C26208E-E0B6-4D78-B9D6-4B45B0D4F653Q40660297-A98DA2E9-FE33-4707-9525-F1FCC515C730Q40792543-3AFA628C-9CBE-42C7-B7E0-2D85F91A2BFEQ41106800-382931F3-B86A-4567-86DF-2690737066C9Q41195276-CA0B105D-D684-4C00-BB0C-C45FEAD8588BQ41728114-46219AC2-FEF7-4643-834E-60E35897B82CQ41914956-2B227ABE-CEB8-4D59-A674-B51746E16F23Q42029373-A0AC4877-F684-4EA5-93D2-1D1BA2258376Q42800638-C9E047C8-120C-42EA-AA20-85EAE2342442Q50291239-1E5BA0FB-BE50-40BB-A1E3-80F77A55E07DQ56336828-1743647D-950E-4A3B-B902-566C6BDD462CQ57584888-0B569DD2-A973-4511-90F7-58F915498AE7Q58719633-8C2DB8F3-BA95-439F-A7E4-98A9D0324A35
P2860
Tissue plasminogen activator: peptide analyses confirm an indirectly derived amino acid sequence, identify the active site serine residue, establish glycosylation sites, and localize variant differences
description
1984 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1984 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 1984
@ast
im Juli 1984 veröffentlicher wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 1984/07/31)
@sk
vědecký článek publikovaný v roce 1984
@cs
wetenschappelijk artikel (gepubliceerd op 1984/07/31)
@nl
наукова стаття, опублікована в липні 1984
@uk
مقالة علمية (نشرت في 31-7-1984)
@ar
name
Tissue plasminogen activator: ...... d localize variant differences
@ast
Tissue plasminogen activator: ...... d localize variant differences
@en
Tissue plasminogen activator: ...... d localize variant differences
@nl
type
label
Tissue plasminogen activator: ...... d localize variant differences
@ast
Tissue plasminogen activator: ...... d localize variant differences
@en
Tissue plasminogen activator: ...... d localize variant differences
@nl
prefLabel
Tissue plasminogen activator: ...... d localize variant differences
@ast
Tissue plasminogen activator: ...... d localize variant differences
@en
Tissue plasminogen activator: ...... d localize variant differences
@nl
P2093
P356
P1433
P1476
Tissue plasminogen activator: ...... d localize variant differences
@en
P2093
H. Jörnvall
M. Källström
N. Bergsdorf
P304
P356
10.1021/BI00311A020
P407
P577
1984-07-31T00:00:00Z